Junshi Bio-U (688180): Treipril's indications for kidney cancer were approved to pioneer the first PD-1 monoclonal antibody immunotherapy for kidney cancer in China
Pacific released a research report on April 8 stating that it gave Junshi Biotech (688180.SH) a purchase rating. The main reasons for the rating include: 1) the company's product sales revenue increased dramatically in 2023, improving overall operating ef
Junshi Biotech (688180): Stable performance growth, PD-1 overseas commercialization can be expected
Junshi Biotech (688180): The company's operational efficiency is steadily improving, and Tuoyi's overseas commercialization is progressing smoothly
Junshi Biotech (1877.HK): PD-1 monoclonal antibody approved by FDA and marketed at an accelerated pace
Junshi Bio-U (688180): The 23-year performance is in line with expectations, the future will continue to focus on innovation and the intensive harvest period is coming
Junshi Biotech (688180): The core pipeline continues to break through, and overseas commercialization of PD-1 can be expected
Junshi Biotech - U (688180): Tripley's volume drives losses to narrow and the company's commercialization capacity continues to improve
Junshi Biotech (688180): Marginal improvement in performance, continued focus on product progress
Junshi Bio-U (688180): International first-class management team upgraded to comprehensively promote the company's domestic and overseas business progress
Junshi Biotech (688180): The company's general manager and CEO changed focus on performance catalysis
Junshi Bio-U (688180): The seventh indication of Trepri was launched to fully open up a new situation of perioperative treatment of lung cancer
Junshi Biotech (688180): Junshi's first domestic breakthrough in perioperative PD-1 indications
Junshi Biotech (688180) Review: Tuoyi was newly approved for NSCLC perioperative indications
Junshi Bio-U (688180): World-class teams join to help the company comprehensively improve Triplet and usher in a new starting point
Research Report Nuggets | Tianfeng Securities: Junshi Biotech Accelerates Late Pipeline R&D and Maintains “Buy” Rating
Junshi Biotech (688180): Accelerate later pipeline development and strengthen the continuous development of core products
Junshi Biotech (688180): International breakthrough, clear PD-1 inflection point
Review of the Junshi Biotech (688180) incident: Treprilizumab has been approved by the FDA for marketing, and the progress of internationalization has reached the next level
Junshi Biotech (688180): Leading enterprises for innovative macromolecule drugs going overseas, high-quality pipelines are progressing steadily
No Data